Premier Asset Managment LLC cut its stake in Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) by 4.7% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 34,840 shares of the biopharmaceutical company’s stock after selling 1,735 shares during the period. Regeneron Pharmaceuticals accounts for approximately 3.5% of Premier Asset Managment LLC’s holdings, making the stock its 5th largest position. Premier Asset Managment LLC’s holdings in Regeneron Pharmaceuticals were worth $14,006,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of the company. Winslow Capital Management LLC bought a new stake in shares of Regeneron Pharmaceuticals during the second quarter valued at $291,760,000. FMR LLC raised its stake in shares of Regeneron Pharmaceuticals by 9.2% in the second quarter. FMR LLC now owns 9,416,836 shares of the biopharmaceutical company’s stock valued at $3,288,642,000 after buying an additional 795,283 shares in the last quarter. Capital World Investors raised its stake in shares of Regeneron Pharmaceuticals by 4.4% in the second quarter. Capital World Investors now owns 7,326,626 shares of the biopharmaceutical company’s stock valued at $2,558,678,000 after buying an additional 312,008 shares in the last quarter. Emerald Acquisition Ltd. bought a new stake in shares of Regeneron Pharmaceuticals during the second quarter valued at $87,319,000. Finally, BlackRock Investment Management LLC raised its stake in shares of Regeneron Pharmaceuticals by 136.0% in the second quarter. BlackRock Investment Management LLC now owns 403,418 shares of the biopharmaceutical company’s stock valued at $140,886,000 after buying an additional 232,471 shares in the last quarter. 68.26% of the stock is currently owned by hedge funds and other institutional investors.

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Shares of Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) traded down 1.77% during mid-day trading on Monday, hitting $391.13. The stock had a trading volume of 521,852 shares. The stock has a market capitalization of $41.00 billion, a P/E ratio of 57.07 and a beta of 1.79. The stock has a 50 day moving average of $381.52 and a 200-day moving average of $389.29. Regeneron Pharmaceuticals Inc. has a 52 week low of $325.35 and a 52 week high of $566.52.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Friday, November 4th. The biopharmaceutical company reported $3.13 EPS for the quarter, beating analysts’ consensus estimates of $2.73 by $0.40. The company had revenue of $1.22 billion for the quarter, compared to analyst estimates of $1.29 billion. Regeneron Pharmaceuticals had a return on equity of 21.51% and a net margin of 16.52%. The company’s quarterly revenue was up 7.3% compared to the same quarter last year. During the same period in the previous year, the company posted $3.47 earnings per share. On average, equities research analysts predict that Regeneron Pharmaceuticals Inc. will post $11.73 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: This news story was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this news story on another domain, it was illegally stolen and republished in violation of United States and international copyright laws. The legal version of this news story can be read at https://www.thecerbatgem.com/2016/11/28/regeneron-pharmaceuticals-inc-regn-is-premier-asset-managment-llcs-5th-largest-position.html.

Several research analysts have recently issued reports on the company. Leerink Swann set a $511.00 price target on Regeneron Pharmaceuticals and gave the stock a “buy” rating in a research note on Saturday, August 6th. RBC Capital Markets reissued a “buy” rating on shares of Regeneron Pharmaceuticals in a research note on Saturday, August 6th. Goldman Sachs Group Inc. reissued a “buy” rating on shares of Regeneron Pharmaceuticals in a research note on Wednesday, August 10th. Piper Jaffray Cos. set a $447.00 price target on Regeneron Pharmaceuticals and gave the stock a “hold” rating in a research note on Sunday, October 30th. Finally, Cowen and Company set a $430.00 price target on Regeneron Pharmaceuticals and gave the stock a “hold” rating in a research note on Sunday, October 30th. One analyst has rated the stock with a sell rating, thirteen have given a hold rating and twelve have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus target price of $468.87.

In related news, Director Joseph L. Goldstein sold 2,125 shares of the company’s stock in a transaction dated Monday, November 14th. The stock was sold at an average price of $450.00, for a total transaction of $956,250.00. Following the sale, the director now owns 15,125 shares in the company, valued at $6,806,250. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Arthur F. Ryan sold 2,000 shares of the company’s stock in a transaction dated Tuesday, November 15th. The stock was sold at an average price of $429.34, for a total value of $858,680.00. Following the sale, the director now owns 36,500 shares in the company, valued at approximately $15,670,910. The disclosure for this sale can be found here. 10.40% of the stock is owned by insiders.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company’s segment includes activities related to the discovery, development and commercialization of pharmaceutical products for the treatment of serious medical conditions.

5 Day Chart for NASDAQ:REGN

Receive News & Stock Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.